Ülke: ABD
Dil: İngilizce
Kaynak: NLM (National Library of Medicine)
Busulfan (UNII: G1LN9045DK) (Busulfan - UNII:G1LN9045DK)
Apotex Corp.
INTRAVENOUS
PRESCRIPTION DRUG
Busulfan injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Busulfan injection is contraindicated in patients with a history of hypersensitivity to any of its components. Risk Summary Busulfan can cause fetal harm when administered to a pregnant woman based on animal data. Busulfan was teratogenic in mice, rats, and rabbits following administration during organogenesis. The solvent, DMA, may also cause fetal harm when administered to a pregnant woman. In rats, DMA doses of approximately 40% of the daily dose of DMA in the busulfan dose on a mg/m2 basis given during organogenesis caused significant developmental anomalies [see Data ]. There are no available human data informing the drug-associated risk. Advise pregnant women of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated populations are unknown. However, t
Busulfan injection is packaged as a sterile clean colorless solution in 10 mL single-dose clear tubular USP type-I glass vial, NDC 60505-6177-0. Busulfan injection is distributed as a unit carton of eight vials NDC 60505-6177-8. Unopened vials of busulfan injection must be stored under refrigerated conditions between 2°C to 8°C (36°F to 46°F). Discard unused portion. Busulfan injection diluted in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP is stable at room temperature (25°C) for up to 8 hours but the infusion must be completed within that time. Busulfan injection diluted in 0.9% Sodium Chloride Injection, USP is stable at refrigerated conditions (2°C to 8°C) for up to 12 hours but the infusion must be completed within that time. Busulfan is a cytotoxic drug. Follow applicable special handling and disposal procedures1 .
Abbreviated New Drug Application
BUSULFAN- BUSULFAN INJECTION APOTEX CORP. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE BUSULFAN INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR BUSULFAN INJECTION. BUSULFAN INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1999 WARNING: MYELOSUPPRESSION _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ • • INDICATIONS AND USAGE Busulfan Injection is an alkylating drug indicated for: • DOSAGE AND ADMINISTRATION • • • DOSAGE FORMS AND STRENGTHS Injection: 60 mg/10 mL (6 mg/mL) single dose vial (3) CONTRAINDICATIONS Busulfan is contraindicated in patients with a history of hypersensitivity to any of its components (4) WARNINGS AND PRECAUTIONS • • • • ADVERSE REACTIONS Most common adverse reactions (incidence greater than 60%) were: myelosuppression, nausea, stomatitis, vomiting, anorexia, diarrhea, insomnia, fever, hypomagnesemia, abdominal pain, anxiety, headache, hyperglycemia and hypokalemia (6.1) TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT APOTEX CORP. AT 1-800-706-5575 OR FDA AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH. DRUG INTERACTIONS Drugs that Decrease Busulfan Clearance: Metronidazole, itraconazole, iron chelating agents, CAUSES SEVERE AND PROLONGED MYELOSUPPRESSION. (5.1) HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION IS REQUIRED TO PREVENT POTENTIALLY FATAL COMPLICATIONS OF THE PROLONGED MYELOSUPPRESSION. (5.1) Use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML) (1) Pre-medicate with anticonvulsants (e.g. benzodiazepines, phenytoin, valproic acid or levetiracetam) and antiemetic (2.1, 5.2) Dilute and administer as intravenous infusion. Do not administer as intravenous push or bolus ( 2.1, 2.3) Recommended adult dose: 0.8 mg per kg of ideal body weight or actual body weight, whichever is lower, administered intravenously via a central venous catheter as a two Belgenin tamamını okuyun